| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
|
J Nucl Med
|
2003
|
3.26
|
|
2
|
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
|
Clin Cancer Res
|
2006
|
2.71
|
|
3
|
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
|
J Nucl Med
|
2009
|
2.12
|
|
4
|
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.
|
Nat Protoc
|
2010
|
2.09
|
|
5
|
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
|
J Nucl Med
|
2008
|
2.08
|
|
6
|
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
|
Eur J Nucl Med Mol Imaging
|
2009
|
2.01
|
|
7
|
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
|
Blood
|
2007
|
1.81
|
|
8
|
Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis.
|
Proc Natl Acad Sci U S A
|
2006
|
1.71
|
|
9
|
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
|
J Nucl Med
|
2009
|
1.68
|
|
10
|
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
|
J Nucl Med
|
2006
|
1.62
|
|
11
|
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.58
|
|
12
|
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
|
J Nucl Med
|
2005
|
1.56
|
|
13
|
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
|
J Nucl Med
|
2003
|
1.56
|
|
14
|
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node.
|
Eur J Nucl Med Mol Imaging
|
2012
|
1.49
|
|
15
|
Basic principles, applications in oncology and improved selectivity of photodynamic therapy.
|
Anticancer Res
|
2003
|
1.48
|
|
16
|
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer.
|
Radiother Oncol
|
2010
|
1.40
|
|
17
|
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.36
|
|
18
|
Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.
|
Mol Imaging
|
2012
|
1.33
|
|
19
|
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
|
Cancer Biother Radiopharm
|
2003
|
1.31
|
|
20
|
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
|
Clin Cancer Res
|
2006
|
1.30
|
|
21
|
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.
|
Cancer Res
|
2009
|
1.28
|
|
22
|
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
|
Mol Cancer Ther
|
2008
|
1.24
|
|
23
|
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
|
J Nucl Med
|
2010
|
1.23
|
|
24
|
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
|
Eur J Nucl Med Mol Imaging
|
2012
|
1.21
|
|
25
|
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
|
Int J Cancer
|
2011
|
1.16
|
|
26
|
Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma.
|
Int J Cancer
|
2003
|
1.12
|
|
27
|
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
|
J Nucl Med
|
2010
|
1.11
|
|
28
|
Multicenter harmonization of 89Zr PET/CT performance.
|
J Nucl Med
|
2013
|
1.07
|
|
29
|
Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
|
J Nucl Med
|
2006
|
0.99
|
|
30
|
Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
|
Clin Cancer Res
|
2003
|
0.99
|
|
31
|
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.99
|
|
32
|
Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.
|
Proc Natl Acad Sci U S A
|
2011
|
0.98
|
|
33
|
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
|
Eur J Nucl Med Mol Imaging
|
2004
|
0.98
|
|
34
|
Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.
|
Clin Cancer Res
|
2004
|
0.96
|
|
35
|
Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.96
|
|
36
|
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
|
Mol Cancer Ther
|
2012
|
0.96
|
|
37
|
Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.
|
Nat Protoc
|
2013
|
0.96
|
|
38
|
Nanobodies in therapeutic applications.
|
Curr Opin Mol Ther
|
2007
|
0.95
|
|
39
|
Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
|
Int J Cancer
|
2002
|
0.94
|
|
40
|
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.93
|
|
41
|
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
|
Drug Discov Today
|
2012
|
0.92
|
|
42
|
Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
|
Cancer Immunol Immunother
|
2003
|
0.91
|
|
43
|
89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals.
|
Curr Top Med Chem
|
2013
|
0.89
|
|
44
|
89Zr-nanocolloidal albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results.
|
J Nucl Med
|
2011
|
0.89
|
|
45
|
Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
|
J Biol Chem
|
2013
|
0.88
|
|
46
|
ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
|
Cancer Biother Radiopharm
|
2013
|
0.85
|
|
47
|
Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach.
|
Bioconjug Chem
|
2011
|
0.85
|
|
48
|
Public-private partnerships in translational medicine: concepts and practical examples.
|
J Control Release
|
2012
|
0.84
|
|
49
|
Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for sentinel node identification in oral cancer patients.
|
J Nucl Med
|
2013
|
0.83
|
|
50
|
Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro.
|
Int J Cancer
|
2002
|
0.83
|
|
51
|
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
|
Clin Cancer Res
|
2003
|
0.83
|
|
52
|
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
|
J Nucl Med
|
2003
|
0.82
|
|
53
|
Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
|
Tumour Biol
|
2007
|
0.81
|
|
54
|
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
|
Clin Cancer Res
|
2002
|
0.81
|
|
55
|
Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.
|
J Nucl Med
|
2013
|
0.80
|
|
56
|
[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
|
Nucl Med Biol
|
2013
|
0.78
|
|
57
|
EATRIS, a vision for translational research in Europe.
|
J Cardiovasc Transl Res
|
2011
|
0.78
|
|
58
|
Three-dimensional histologic validation of high-resolution SPECT of antibody distributions within xenografts.
|
J Nucl Med
|
2014
|
0.77
|
|
59
|
Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model.
|
ChemMedChem
|
2015
|
0.76
|
|
60
|
Radioimmunodetection and radioimmunotherapy of head and neck cancer.
|
Oral Oncol
|
2004
|
0.76
|
|
61
|
The potential role of non-FDG-PET in the management of head and neck cancer.
|
Oral Oncol
|
2010
|
0.75
|
|
62
|
Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
|
BioDrugs
|
2006
|
0.75
|